Zurcher Kantonalbank Zurich Cantonalbank Increases Position in Insulet Co. (NASDAQ:PODD)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Insulet Co. (NASDAQ:PODD) by 15.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,319 shares of the medical instruments supplier’s stock after purchasing an additional 5,031 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Insulet were worth $8,686,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in PODD. QRG Capital Management Inc. acquired a new stake in shares of Insulet in the third quarter valued at approximately $297,000. Diversified Trust Co grew its holdings in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after buying an additional 4,348 shares in the last quarter. Linden Thomas Advisory Services LLC increased its stake in shares of Insulet by 65.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock worth $1,778,000 after acquiring an additional 3,497 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Insulet by 38.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock worth $36,202,000 after acquiring an additional 50,101 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after acquiring an additional 3,113 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on PODD shares. UBS Group lifted their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. BTIG Research upped their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Price Performance

Insulet stock opened at $266.78 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The firm has a market cap of $18.71 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The company’s 50 day moving average is $244.40 and its two-hundred day moving average is $214.14.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.